Board of Directors
Michael P. Whitman | Founder, President & CEO
Michael Whitman is the founder and CEO of Micro Interventional Devices, Inc. (MID). Michael has over 30 years of medical device experience at market leading firms including, Johnson and Johnson, Olympus, Synthes and Power Medical Interventions. He previously was the founder and CEO of Power Medical Interventions (NASDAQ; PMII), which was acquired by Covidien Ltd. in 2009. Prior to founding PMI, Michael served in numerous management positions at Johnson and Johnson during his 13-year tenure including Vice President of Sales, Director of Sales and Marketing, Product Development and Product Management. He is the named inventor on over 35 US and foreign patents. He received his A.B. in Business and Economics from Lafayette College and completed graduate work at Wharton, University of Michigan, Harvard Executive Education, and Rutgers University.
Gerald Dorros | Gerald Dorros, MD, ScD, FACC, FESC, FACP, FSVMB, FAHA (emeritus), FCCP, FACA, Medical Director of the Dorros Fueur Interventional Cardiovascular Disease Foundations Ltd.
Gerald Dorros, M.D. was the third individual to perform angioplasty in the US in 1978. He initiated the use of angioplasty as a primary therapy for peripheral vascular disease in 1979, and is a world-renowned cardiovascular interventionalist. He is the Medical Director of the Dorros Feuer Interventional Cardiovascular Disease Foundation Ltd. Dr. Dorros previously served as President of the Arizona Heart Institute Foundation and previously was a partner of the Milwaukee Heart and Vascular Clinic. He has made numerous contributions to the management of heart and peripheral vascular disease, renovascular hypertension and critical limb ischemia, including pioneering work in stent supported renal angioplasty, carotid stent supported angioplasty, and endovascular repair of thoracic and abdominal aortic aneurysm in high-risk surgical patients. Dr. Dorros has an exceptional understanding of how less invasive procedures, enabled by new technologies, can benefit patients.
Mike Gausling | Managing Partner, Originate Ventures, LLC
Mike Gausling is a co-founder and Managing Partner of Originate Ventures LLC, a venture capital investment firm which targets early stage and emerging growth product companies in Eastern Pennsylvania. Prior to Originate Ventures, Mike was a co-founder and former CEO of OraSure Technologies (NASDAQ: OSUR), where he helped build the company from a start-up to more than $50 million in annual sales and a market cap of over $500 million.Mike is the Treasurer of Lehigh Valley Industrial Park (LVIP), a local non-profit land development company and a Board member for the Community Action Committee of the Lehigh Valley. Mike earned a BS in Mechanical Engineering from Rensselaer Polytechnic Institute and received an MBA in Finance from Miami University of Ohio.
Thomas Osypka | Chief Executive Officer and President, Oscor, Inc.
Thomas Osypka is the owner, Chief Executive Officer and President of Oscor, Inc., a leading medical device company and contract manufacturer of minimally invasive and long term implantable devices and delivery systems for Cardiac Rhythm Management, Interventional Cardiology and Structural Heart. With over 25 year of experience in the medical device industry, Mr. Osypka transformed Oscor from a domestic manufacturer of implantable cardiac leads to a completely vertically integrated medical device and contract manufacturing company with global presence suppling the medical device industry with innovative turnkey development and manufacturing solutions. He currently serves as a board member and investor in several medical device companies. Mr. Osypka holds a Master's Degree in Electrical Engineering from the Konstanz University of Applied Science in Germany.
Christopher Thatcher | Chief Executive Officer and President, Neuronetics, Inc.
Christopher A. Thatcher is the President and Chief Executive Officer at Neuronetics, Inc. He has over 20 years of experience specializing in the development and successful commercialization of new medical device products. Currently at Neuronetics, Mr. Thatcher is the driving force for this pioneer and innovator in Transcranial Magnetic Stimulation therapy for Major Depressive Disorder. His focus is on continuing to accelerate its position as a global market leader in TMS with the NeuroStar TMS Therapy System. Mr. Thatcher has previously held executive positions at Reichert Technologies, a unit of AMETEK Ultra Precision Technologies, Integra Lifesciences, Bausch and Lomb, and Allergan. His strengths in optimizing product development, strategic decision-making, and streamlining operations will be of great value to MID.